All In Biotech

Drug Trial Radar · NCT06985147

A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)

A Phase 2, Open-Label Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DISC-3405 in Participants With Polycythemia Vera (PV)

Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Aug 12, 2025

Primary completion

Jul 2027

Study completion Jul 2029

Sponsor

Lead sponsor
Disc Medicine, IncIndustry
Sponsor type
Industry
First posted
May 22, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This open-label, multicenter, within-participant dose escalation study examining up to 2 dose levels of DISC-3405 will assess the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of DISC-3405 in participants with polycythemia vera (PV).

Conditions

  • Polycythemia Vera (PV)

Interventions

  • DISC-3405Drug

    DISC-3405 is administered subcutaneously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with treatment-related adverse events as assessed by CTCAETime frame: Up to 365 days
  2. Incidence of clinically abnormal vital signsTime frame: Up to 365 days
  3. Incidence of clinically abnormal physical examTime frame: Up to 365 days
  4. Incidence of clinically abnormal electrocardiogramsTime frame: Up to 365 days
  5. Incidence of abnormal laboratory test resultsTime frame: Up to 365 days

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic in Arizona

    Phoenix, Arizona

  • USC Norris Comprehensive Cancer Center

    Los Angeles, California

  • UCLA Health

    Los Angeles, California

  • Keck Medicine of USC - Cancer Clinic- Newport Beach

    Newport Beach, California

  • Mayo Clinic in Florida

    Jacksonville, Florida

  • Mayo Clinic in Minnesota

    Rochester, Minnesota

  • Siteman Cancer Center - Washington University St. Louis

    St Louis, Missouri

  • Atrium Health - Levine Cancer Center

    Charlotte, North Carolina

  • Duke University

    Durham, North Carolina

  • Atrium Health Wake Forest Baptist Medical Center

    Winston-Salem, North Carolina

  • Cleveland Clinic

    Cleveland, Ohio

  • Ohio State University

    Columbus, Ohio

  • Oregon Health & Science University

    Portland, Oregon

  • MD Anderson Cancer Center

    Houston, Texas

  • University of Washington - Fred Hutchinson Cancer Research Center

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.